Literature DB >> 16156153

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.

Philip J Rosenfeld1, Anne E Fung, Carmen A Puliafito.   

Abstract

To determine whether bevacizumab could improve visual acuity and optical coherence tomography outcomes in a patient with macular edema from central retinal vein occlusion, an intravitreal injection of bevacizumab (1.0 mg) was given. Prior intravitreal injections of triamcinolone acetonide resulted in vision improvement but worsening cataract and borderline glaucoma. Within 1 week of the bevacizumab injection, visual acuity improved from 20/200 to 20/50 and optical coherence tomography revealed resolution of the cystic maculopathy. The improvements were maintained for at least 4 weeks. Intravitreal injections of bevacizumab may provide another treatment option for patients with macular edema from vein occlusions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156153

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  118 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Relationship between perifoveal capillaries and pathomorphology in macular oedema associated with branch retinal vein occlusion.

Authors:  T Murakami; A Tsujikawa; K Miyamoto; A Sakamoto; M Ota; K Ogino; N Yoshimura
Journal:  Eye (Lond)       Date:  2012-06-01       Impact factor: 3.775

3.  Adverse skin reactions following intravitreal bevacizumab injection.

Authors:  S Ameen; M Entabi; N Lee; A Stavrakoglou
Journal:  BMJ Case Rep       Date:  2011-03-01

4.  Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion.

Authors:  Masafumi Ota; Akitaka Tsujikawa; Kazuaki Miyamoto; Atsushi Sakamoto; Tomoaki Murakami; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

Review 5.  Vascular endothelial growth factor biology: clinical implications for ocular treatments.

Authors:  R B Bhisitkul
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

6.  Effects of bevacizumab on retinal function in isolated vertebrate retina.

Authors:  M Lüke; M Warga; F Ziemssen; F Gelisken; S Grisanti; T Schneider; C Lüke; M Partsch; K U Bartz-Schmidt; P Szurman
Journal:  Br J Ophthalmol       Date:  2006-06-05       Impact factor: 4.638

7.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

8.  Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Authors:  P J Rosenfeld
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

9.  Effect of posterior sub-tenon triamcinolone in macular edema due to non-ischemic vein occlusions.

Authors:  Murali Mohan Gurram
Journal:  J Clin Diagn Res       Date:  2013-09-13

10.  Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.

Authors:  Young Sang Han; Ji Eun Lee; Ji Won Jung; Jong Soo Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-25       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.